Literature DB >> 20079562

Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.

Zhizhen Qi1, Lei Zhou, Qingwen Zhang, Lingling Ren, Ruixia Dai, Benchuan Wu, Tang Wang, Ziwen Zhu, Yonghai Yang, Baizhong Cui, Zuyun Wang, Hu Wang, Yefeng Qiu, Zhaobiao Guo, Ruifu Yang, Xiaoyi Wang.   

Abstract

In this study, a new subunit vaccine that comprised native F1 and recombinant rV270 was evaluated for protective efficacy using mouse, guinea pig and rabbit models in comparison with the live attenuated vaccine EV76. Complete protection against challenging with 10(6) colony-forming units (CFU) of virulent Yersinia pestis strain 141 was observed for mice immunized with the subunit vaccines and EV76 vaccine. In contrast, the subunit vaccine recipes VII (F1-20 microg+rV270-10 microg) and IX (F1-40 microg+rV270-20 microg) and EV76 vaccine provided 86%, 79% and 93% protection against the same level of challenge in guinea pigs and 100%, 83% and 100% protection in rabbits, respectively. The immunized mice with the vaccines had significantly higher IgG titres than the guinea pigs and rabbits, and the immunized guinea pigs developed significantly higher IgG titres than the rabbits, but the anti-F1 response in guinea pigs was more variable than in the mice and rabbits, indicating that guinea pig is not an ideal model for evaluating protective efficacy of plague subunit vaccine, instead the rabbits could be used as an alternative model. All the immunized animals with EV76 developed a negligible IgG titre to rV270 antigen. Furthermore, analysis of IgG subclasses in the immunized animals showed a strong response for IgG1, whereas those receiving EV76 immunization demonstrated predominant production of IgG1 and IgG2a isotypes. The subunit vaccine and EV76 vaccine are able to provide protection for animals against Y. pestis challenge, but the subunit vaccines have obvious advantages over EV76 in terms of safety of use. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20079562     DOI: 10.1016/j.vaccine.2009.02.078

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

2.  Acquisition of maternal antibodies both from the placenta and by lactation protects mouse offspring from Yersinia pestis challenge.

Authors:  Zhizhen Qi; Haihong Zhao; Qingwen Zhang; Yujing Bi; Lingling Ren; Xuecan Zhang; Hanqing Yang; Xiaoyan Yang; Qiong Wang; Cunxiang Li; Jiyuan Zhou; Youquan Xin; Yonghai Yang; Huiying Yang; Zongmin Du; Yafang Tan; Yanping Han; Yajun Song; Lei Zhou; Pingping Zhang; Yujun Cui; Yanfeng Yan; Dongsheng Zhou; Ruifu Yang; Xiaoyi Wang
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

3.  Humoral and cellular immune responses to Yersinia pestis infection in long-term recovered plague patients.

Authors:  Bei Li; Chunhong Du; Lei Zhou; Yujing Bi; Xiaoyi Wang; Li Wen; Zhaobiao Guo; Zhizhong Song; Ruifu Yang
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

4.  Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.

Authors:  Lanying Du; Xiujuan Zhang; Jixiang Liu; Shibo Jiang
Journal:  J Vis Exp       Date:  2011-05-02       Impact factor: 1.355

Review 5.  Plague Vaccines: Status and Future.

Authors:  Wei Sun
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

6.  Long-term observation of subunit vaccine F1-rV270 against Yersinia pestis in mice.

Authors:  Zuyun Wang; Lei Zhou; Zhizhen Qi; Qingwen Zhang; Ruixia Dai; Yonghai Yang; Baizhong Cui; Hu Wang; Ruifu Yang; Xiaoyi Wang
Journal:  Clin Vaccine Immunol       Date:  2009-11-25

7.  Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.

Authors:  Bethany L Tiner; Jian Sha; Duraisamy Ponnusamy; Wallace B Baze; Eric C Fitts; Vsevolod L Popov; Christina J van Lier; Tatiana E Erova; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2015-10-07

8.  Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques.

Authors:  Qingwen Zhang; Qiong Wang; Guang Tian; Zhizhen Qi; Xuecan Zhang; Xiaohong Wu; Yefeng Qiu; Yujing Bi; Xiaoyan Yang; Youquan Xin; Jian He; Jiyuan Zhou; Lin Zeng; Ruifu Yang; Xiaoyi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-11-13       Impact factor: 3.452

Review 9.  Rational considerations about development of live attenuated Yersinia pestis vaccines.

Authors:  Wei Sun; Roy Curtiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Model systems to study plague pathogenesis and develop new therapeutics.

Authors:  Matthew B Lawrenz
Journal:  Front Microbiol       Date:  2010-11-04       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.